Page last updated: 2024-11-10

lasiocarpine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

lasiocarpine: RN given refers to parent cpd(1S-(1alpha(Z),7(2S*,3R*),7aalpha))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6325507
CHEBI ID6382
MeSH IDM0046462

Synonyms (8)

Synonym
303-34-4
lasiocarpine
7-angelyl-9-lasiocarpylheliotridine
CHEBI:6382
Q27107185
HY-121390
CS-0081847
AKOS040744612

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" LC was slightly more toxic to control hepatocytes than SC in the graded response range of 10-160 microM."( Influences of various xenobiotic inducers on cytocidal toxicity of lasiocarpine and senecionine in primary cultures of rat hepatocytes.
Cameron, RC; Farber, E; Hayes, MA; Jago, MV; Roberts, E; Safe, SH, 1984
)
0.27
" Up to now, only few in vitro and in vivo investigations were performed to evaluate their relative toxic potential."( Development of an in vitro screening method of acute cytotoxicity of the pyrrolizidine alkaloid lasiocarpine in human and rodent hepatic cell lines by increasing susceptibility.
Disch, L; Drewe, J; Forsch, K; Schöning, V; Siewert, B; Unger, M, 2018
)
0.48
" At concentrations of 25 µM up to even 2400 µM, no toxic effects in neither cell line was observed with standard cell culture media."( Development of an in vitro screening method of acute cytotoxicity of the pyrrolizidine alkaloid lasiocarpine in human and rodent hepatic cell lines by increasing susceptibility.
Disch, L; Drewe, J; Forsch, K; Schöning, V; Siewert, B; Unger, M, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Deaths occurred in all dosed groups and increased with dietary seed concentration."( Toxicity of dietary Heliotropium dolosum seed to mice.
Akyüz, C; Eröksüz, H; Eröksüz, Y; Ozer, H; Sener, B; Tosun, F, 2001
)
0.31
" Concentration-response curves obtained from in vitro cytotoxicity assays in primary rat hepatocytes were converted to in vivo dose-response curves from which points of departure (PODs) were derived and that were compared to available literature data on in vivo liver toxicity."( Use of physiologically based kinetic modelling-facilitated reverse dosimetry to convert in vitro cytotoxicity data to predicted in vivo liver toxicity of lasiocarpine and riddelliine in rat.
Chen, L; Louisse, J; Ning, J; Rietjens, IMCM; Wesseling, S, 2018
)
0.48
" The concentration-response curves of in vitro cytotoxicity of lasiocarpine and riddelliine defined in pooled human hepatocytes were translated to in vivo dose-response curves by PBK models developed using kinetic data obtained from incubations with pooled tissue fractions from Chinese and Caucasian individuals, providing PBK models for the average Chinese and average Caucasian, respectively."( Use of an in vitro-in silico testing strategy to predict inter-species and inter-ethnic human differences in liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine.
Chen, L; Louisse, J; Ning, J; Rietjens, IMCM; Strikwold, M; Wesseling, S, 2019
)
0.51
" The in vitro concentration-response curves obtained from primary rat hepatocytes were subsequently converted to in vivo dose-response curves from which points of departure (PoDs) were derived that were compared to available in vivo genotoxicity data."( Prediction of in vivo genotoxicity of lasiocarpine and riddelliine in rat liver using a combined in vitro-physiologically based kinetic modelling-facilitated reverse dosimetry approach.
Chen, L; de Haan, L; Peijnenburg, A; Rietjens, IMCM, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrrolizines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (34.29)18.7374
1990's2 (5.71)18.2507
2000's3 (8.57)29.6817
2010's15 (42.86)24.3611
2020's3 (8.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.78%)6.00%
Case Studies1 (2.78%)4.05%
Observational0 (0.00%)0.25%
Other34 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]